Spectrum Pharmaceuticals Suspends Phase 3 Poziotinib Trial in HER2 NSCLC
The registry entry for the poziotinib study in HER2 exon 20-mutated lung cancer now reads SUSPENDED, with no patients enrolled and a redesign under discussion with the FDA.
Spectrum Pharmaceuticals has put its phase 3 study of poziotinib on hold. The trial, registered as NCT05378763, tests the drug in previously treated patients with locally advanced or metastatic non-small cell lung cancer carrying HER2 exon 20 mutations. The ClinicalTrials.gov record was updated on 1 September 2026 and now carries the status SUSPENDED.
The stated reason is twofold. According to the registry, the study has not enrolled any patients, and the sponsor adds that the study design is under discussion and will likely be redesigned in consultation with the FDA. In other words, the programme is being paused before it ever started dosing, not halted because of a safety signal in participants.
That distinction matters for interpretation. A suspension with zero enrolment points to a protocol and regulatory question rather than an emerging toxicity or futility finding. It also means no interim efficacy data from this study exists to be disclosed.
The indication itself is a narrow but competitive niche. HER2 exon 20 insertion mutations occur in a small subset of NSCLC patients, and a phase 3 registration study is normally the final step toward a marketing application. Redesigning that study in consultation with the FDA typically resets timelines rather than shortening them.
For Spectrum, poziotinib has been the central late-stage asset in its oncology pipeline, which makes any change to the confirmatory study materially relevant. The registry does not specify how long the suspension will last, what the revised design might look like, or when enrolment could begin.
No further financial or clinical detail was provided in the update. Investors following the programme will be dependent on the company's own disclosures for the outcome of the discussions with the regulator.
This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.
